With this acquisition, Salarius has gone from a company with a single clinical-stage investigational drug asset, seclidemstat, to a company with a multi-prong internal pipeline built around two exciting and distinct fields of cancer drug research – protein inhibition and targeted protein degradation.....
Insiders are in possession of 0.40% of company’s total shares while institution are holding 19.26 percent of that, with stock having share float percentage of 19.34%.
next quarterly report between March 16 and March 21 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
alert: Compliance for the $1.00 bid rule must be regained by 05/16/2022. Not including the possibility of a 180 day extension
we have all the cards in hand!
News 
Market Data 
Discover 
